Track market-moving stories before they get noisy

, /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Celsius Holdings, Inc. ("Celsius" or the "Company") (NASDAQ: CELH) and certain officers.   The class action, filed in the United States District Court for the Southern District of Florida, and docketed under 26-cv-62465, is on behalf of a class consisting of all persons and entities other than Defendants that purchased or otherwise acquired Celsius securities between February 21, 2025 and June 3, 2026, both dates inclusive (the "Class Period"), seeking to recover damages caused by Defendants' violations of the federal securities laws and to pursue remedies under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder, against the Company and certain of its top officials.

If you are an investor who purchased or otherwise acquired Celsius securities during the Class Period, you have until November 3, 2026, to ask the Court to appoint you as Lead Plaintiff for the class.  A copy of the Complaint can be obtained at www.pomerantzlaw.com.  To discuss this action, contact Danielle Peyton at [email protected] or 646-581-9980 (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased. 

[Click here for information about joining the class action]

Celsius develops, processes, manufactures, markets, sells, and distributes products including energy drinks.

On April 1, 2025, Celsius closed the acquisition of Alani Nutrition LLC ("Alani Nu"), a maker of highly caffeinated energy drinks (described in greater detail below), for a net purchase price of $1.65 billion, comprised of cash and stock.

At all relevant times, Defendants represented that their products, including specifically Alani Nu drinks, were safe and healthy. For example, as of the time this Complaint was filed, Alani Nu's website continues to represent that "we use ingredients you can feel good about without compromising taste."

However, in contrast to Defendants' representations, Alani Nu drinks present serious risks due to the amount of caffeine they contain. A single 12-ounce Alani Nu drink contains 200 milligrams of caffeine, more than other popular energy drinks and more than twice the 100-milligram daily limit of caffeine recommended for teenagers and children aged 12 to 17, according to leading bodies of pediatricians and adolescent psychiatrists. The Center for Disease Control has stated that consumption of energy drinks in this age range can lead to cardiovascular issues ranging from irregular heartbeat to heart failure.

Alani Nu drinks have previously been the subject of regulatory action. In August of 2023, the Canadian Food Inspection Agency warned Canadians "[d]o not consume, use, sell, serve, or distribute" Alani Nu energy drinks, stating that the drinks "are being recalled from the marketplace due to various non-compliances related to caffeine content and labelling requirements." Specifically, Alani Nu's caffeine content exceeded Canada's legal limit of 180 milligrams for a single-serving energy drink.

Despite the risks that Alani Nu drinks present to consumers under the age of 18, Defendants at all relevant times have marketed these drinks to such consumers despite asserting their purported commitment not to do so. Alani Nu drinks are packaged in dynamic, bright colors, and Alani Nu actively recruits college students to join the "Alani Ambassadors" program and market Alani Nu products using their profiles on social media platforms such as Instagram and TikTok. As of the filing of this Complaint, the Alani Nu website even concedes that Defendants work with individuals whose social media audiences are comprised up to 25% of individuals under the age of 18.

While the labels on Alani Nu energy drinks state the amount of caffeine one can contains and generally state that they are "not recommended for consumption by children", they contain no similar cautionary language with respect to teenagers.

The complaint alleges that, throughout the Class Period, Defendants made materially false and misleading statements regarding the Company's business, operations, and compliance policies. Specifically, Defendants made false and/or misleading statements and/or failed to disclose that: (i) Defendants' products failed to adequately disclose the cardiac risks of consuming Alani Nu products; (ii) by marketing Alani Nu drinks to consumers under the age of 18, the Company was marketing its products to individuals who were particularly susceptible to known health risks posed by those products; (iii) the foregoing created a non-speculative risk that Alani Nu consumers would suffer potentially fatal adverse health events; (iv) the foregoing, once revealed, was likely to have a significant negative impact on the Company's business and reputation; and (v) as a result, Defendants' public statements were materially false and misleading at all relevant times.

The truth began to emerge on April 9, 2026, when NBC News and local news outlet MyRGV (Rio Grande Valley) reported that the family of 17-year old Texas cheerleader Larissa Rodriguez had filed a wrongful death lawsuit in Hidalgo County District Court against Glazer's Beer and Beverage, LLC ("Glazer's") and Glazer's Beer and Beverage of Texas, LLC, two distributors of Alani Nu. The family alleged that Rodriguez died from an enlarged heart caused by drinking Alani Nu energy drinks and that the drinks "had inadequate warnings about the serious cardiac risks" of drinking Alani Nu. According to NBC News, Celsius stated in response, inter alia, "our policy is not to market or sample to anyone under 18".

On this news, Celsius's stock price fell $1.52 per share, or 4.18%, to close at $34.86 on April 10, 2026.

Then, on June 4, 2026, Texas Attorney General Ken Paxton ("Paxton") announced an investigation into Celsius over concerns that its high-caffeine energy drinks are being marketed to children and teens. Per Attorney General Paxton's announcement, the investigation will specifically examine whether Celsius and its Alani Nu subsidiary had violated the Texas Deceptive Trade Practices Act by misrepresenting the safety of their products.

On news of the investigation, Celsius's stock price fell $2.26 per share, or 7.53%, to close at $27.75 per share on June 4, 2026.

Pomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered billions of dollars in damages awards on behalf of class members. See www.pomlaw.com.

Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:
Danielle Peyton
Pomerantz LLP
[email protected]
646-581-9980 ext. 7980

SOURCE Pomerantz LLP

BlackBerry Shifts Gears With Coretura DealMobileye Global NASDAQ: MBLY said its core advanced driver-assistance systems business has strengthened in 2026, while the company works to expand its higher-content hands-free driving offerings and develop a more vertically integrated robotaxi strategy.

Speaking with Evercore ISI Head of Global Auto and Mobility Chris McNally, Chief Communications Officer Dan Galves acknowledged that several anticipated SuperVision partnerships “didn't really materialize” in their first round. Still, he said the company sees reasons for optimism in its core ADAS business, emerging-market growth and planned launches with automakers including Porsche.

Get Mobileye Global alerts:

Core ADAS Volume Outlook Improves 3 Robotics Stocks Under $10: Value, Momentum, or Bet?Galves said Mobileye expects approximately 10% volume growth based on its July guidance, compared with an original expectation for 4% growth. He attributed the projected growth to roughly 3% from China exports, 3% from first-quarter safety-stock increases and 4% growth among its top 10 customers.

That customer growth compares with an estimated 5% decline in global production among those top 10 OEM customers, according to Galves. He said the company’s growth relative to customer production reflects strong performance despite a sluggish broader auto-production environment.

Forget Tesla: These 2 Earnings Reports Reveal Where the Auto Market Is HeadingChina-based automakers have increased exports as their domestic market remains weak, Galves said. Mobileye has stronger share on export vehicles, particularly with Chery and Geely, than it does on vehicles sold in China. He said exports are reaching markets including Russia, Brazil, Malaysia and Australia, rather than being concentrated in Western Europe.

According to Galves, low ADAS penetration in those markets is prompting legacy automakers to standardize more ADAS content. He cited S&P data showing about 1 million to 1.5 million units of emerging-market ADAS adoption growth this year and said Mobileye expects that figure could be revised higher.

Looking further ahead, Galves identified India as a significant potential growth market, citing Mobileye’s position with Mahindra and Tata as well as regulations expected in 2027. However, he said growth beyond roughly 40 million units will not be easy because of production declines among some major customers and already-high ADAS penetration in North America and Western Europe.

Hands-Free Systems Offer Higher Content Opportunity Mobileye sees highway hands-free Level 2+ systems as the largest near-term growth opportunity in ADAS. Galves distinguished those products from point-to-point systems, which can drive a vehicle to a destination across varied road types and conditions.

While point-to-point systems such as Tesla’s Full Self-Driving receive considerable attention, Galves said highway hands-free systems are expected to account for more volume over the next several years. He cited an estimated 18% compound annual growth rate for the segment over the next two to three years.

The company has secured two major new “Surround ADAS” programs with Volkswagen and a large U.S. OEM, Galves said, while BMW elected to continue working with Qualcomm. Surround ADAS includes multiple cameras, radars, an EyeQ6 High processor and Mobileye-provided software for capabilities including parking and driver monitoring.

Galves said the systems can lower costs for automakers. In one program, he said Mobileye expects to reduce the OEM’s current cost to approximately $400 from about $1,200. The company expects Surround ADAS to generate two to three times the average selling price of a base system while maintaining the same gross-margin profile.

Mobileye also discussed its Cloud-Enhanced ADAS offering, which Stellantis selected to add REM road intelligence to an existing EyeQ6 Lite program. Galves said the upgrade can increase average selling price to about $90 from $50, while gross profit per unit is similar to the more comprehensive Surround ADAS system.

Porsche Launch Seen as SuperVision Proof Point Galves said Mobileye’s SuperVision system with Porsche is scheduled to launch next year and could become an important proof point for its point-to-point capabilities. He said the Porsche program continues to indicate annual volume of roughly 300,000 to 350,000 units after several years, rather than in the initial 2027 launch year.

He said the launch could provide evidence that Mobileye can execute a next-generation system that competes with Tesla’s FSD. The company has also received calls concerning possible fallback programs, Galves said, as automakers pursue multi-supplier approaches and seek to retain their own intellectual property in point-to-point autonomy programs.

For its Chauffeur program with Audi, Galves said development is making good progress and remains on track for a planned second-quarter 2028 launch, though “a lot of work” remains.

Robotaxi Efforts Expand Beyond OEM Partnerships Mobileye said its existing robotaxi partnerships are advancing. Closed-user-group testing with Volkswagen ID. Buzz vehicles has begun in Orlando and has been underway for months in Hamburg, both with safety drivers. Los Angeles testing is occurring in Santa Monica and West Hollywood, while Oslo and Berlin are also target cities.

Galves said Mobileye’s partner HOLON, owned by BENTELER Group, has been selected as the production autonomous-vehicle partner for Deutsche Bahn’s KIRA initiative. The program is intended to integrate autonomous vehicles into public transportation in multiple German regions.

Mobileye is also pursuing its own vertically integrated robotaxi platform. Galves said the company intends to have vehicles delivered from automakers without self-driving equipment to an upfit facility, after which Mobileye would own the completed vehicle. That structure would allow the company to sell or lease vehicles to operators, deploy them in its own service, or use them in third-party services.

The company does not intend to necessarily operate a fully vertically integrated service in direct competition with Waymo, Galves said. Instead, it aims to establish a complete service and demonstrate driverless operation to improve its negotiating position with potential fleet-scale partners.

Galves said Mobileye expects to have AV-ready vehicles by the end of the year or early 2027 and believes an OEM could produce a purpose-designed variation of an existing vehicle platform in the thousands annually. He said the company believes it can bring the bill of materials cost for its self-driving system below $10,000, excluding the cost of the vehicle itself.

About Mobileye Global (NASDAQ:MBLY)Mobileye Global Inc is a technology company focused on advanced driver-assistance systems (ADAS) and autonomous driving. Its technologies are designed to help improve road safety and support automated driving through computer vision, artificial intelligence, sensor fusion and mapping.

The company develops and supplies products for automakers and mobility providers, including EyeQ system-on-chips, camera-based driver-assistance features, SuperVision hands-free driving technology, and autonomous driving platforms.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to [email protected].

Should You Invest $1,000 in Mobileye Global Right Now?Before you consider Mobileye Global, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Mobileye Global wasn't on the list.

While Mobileye Global currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.

Get This Free Report

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

AMSTERDAM--(BUSINESS WIRE)--Nebius (Nasdaq: NBIS), the AI cloud company, today announced it has acquired Inferize, an inference optimization company whose technology shortens the time needed to launch and scale large AI models, making inference workloads elastic.

Inferize's technology and team have joined Nebius Token Factory, Nebius's managed inference platform for production AI.

Cold starts – the time models need to load before serving a single request – impose additional time and costs on teams running AI models in production at scale. This leaves assigned GPUs idle at launch time, when demand spikes and new instances spin up, and when weights are updated mid-run for example during reinforcement learning – and forces platforms to hold spare capacity just to hit their service-level targets.

Inferize's technology cuts this “idle GPU tax”, enabling capacity to scale much more closely with actual usage and driving higher capacity utilization and better token economics.

Danila Shtan, Chief Technology Officer of Nebius, said:
“Running inference well takes more than fast GPUs and optimized models. The whole system needs to respond when demand changes, including how quickly additional capacity is ready to serve customers. Inferize brings technology that accelerates that process and a team with deep expertise in GPU systems. We’re bringing both into Token Factory to make it more responsive to customer demand and get more useful work out of our infrastructure. The team’s contribution will extend well beyond this first integration.”

Inferize adds another layer to how Nebius runs production inference. Eigen AI brought optimization at the model, kernel and system levels into Nebius Token Factory, while Clarifai's core team and licensed technology added system-level inference and compute orchestration.

Guy Bortnikov, co-founder and CEO of Inferize, said:
"Keeping spare GPUs running is the price of being ready for demand. Removing that cost is what we built Inferize to do, and Nebius is where it can go straight into the platform. Our team will work across the stack with one objective: serving more customer demand from every GPU."

Founded in January 2026, the Inferize team had a working prototype within three months. Inferize’s engineers will work across Nebius Token Factory, starting with the integration of their technology.

The terms of the transaction were not disclosed.

About Nebius

Nebius, the AI cloud company, is building the full-stack platform for developers and companies to take charge of their AI future — from data and model training to production deployment. Founded on deep in-house technological expertise and operating at scale with a rapidly expanding global footprint, Nebius serves startups and enterprises building AI products, agents, and services worldwide.

Nebius is listed on Nasdaq (Nasdaq: NBIS) and headquartered in Amsterdam.

For more information please visit nebius.com.

Media kit nebius.com/media-kit.

Disclaimer

Forward-looking statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, which involve risks and uncertainties. All statements contained in this press release other than statements of historical fact, including, without limitation, statements regarding our future financial and business performance, strategy, expected growth, planned investments and capital expenditures, capacity expansion plans, anticipated future financing transactions and expected financial results, are forward-looking statements. The words "anticipate," "believe," "continue," "estimate," "expect," "guide," "intend," "likely," "may," "will" and similar expressions and their negatives are intended to identify forward-looking statements.

These forward-looking statements are subject to risks, uncertainties and assumptions, some of which are beyond our control. Actual results may differ materially from the results predicted or implied by such statements, and our reported results should not be considered as an indication of future performance. The potential risks and uncertainties that could cause actual results to differ from the results predicted or implied by such statements include, among others: market, macroeconomic and geopolitical conditions; our ability to build, operate and manage our businesses to the desired scale; competitive pressures; technological developments; our ability to secure and retain clients; our ability to secure additional capital to enable the growth of the business; unpredictable sales cycles; and potential pricing pressures; as well as those risks and uncertainties related to our continuing businesses included under the captions "Risk Factors" and "Operating and Financial Review and Prospects" in our Annual Report on Form 20-F for the year ended December 31, 2025, filed with the SEC on April 30, 2026, which is available on our investor relations website at https://nebius.com/investor-hub and on the SEC website at www.sec.gov.

All information in this press release is as of the date hereof (unless stated otherwise). Except as required by law, we undertake no obligation to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise, after the date on which the statements are made or to reflect the occurrence of unanticipated events.

In addition, statements that "we believe" and similar statements reflect our beliefs and opinions on the relevant subject. These statements are based upon information available to us as of the date hereof and, while we believe such information forms a reasonable basis for such statements, such information may be limited or incomplete, and our statements should not be read to indicate that we have conducted an exhaustive inquiry into, or review of, all potentially available relevant information. These statements are inherently uncertain, and investors are cautioned not to unduly rely upon these statements.

Sigma Lithium Corp (TSX-V:SGML, NASDAQ:SGML, ASX:SAU) said on Thursday it still expects to deliver 330,000 tonnes of lithium oxide concentrate in fiscal 2027, even as it temporarily suspended mining and industrial production in Brazil. 

The company halted operations on September 30 after a 15-day delay by the Federal Court of Appeals in reviewing its emergency motion for suspensive relief. It will postpone by three months its 12-month guidance of 240,000 tonnes. 

Sigma will keep its commercial and recycling operations running, including the recycling of 100% of its dry stacked tailings and sales of high-purity lithium fines. The company expects those activities to generate cash flow and self-fund it during the suspension. 

The case stems from a lawsuit filed by the NGO Ngolo seeking to suspend the company's environmental licences. Sigma said its Grota do Cirilo complex sits outside the Quilombo and the legal distance of environmental impact set by Brazilian law. It said the community's houses are about 11 km from the Barreiro Pit and 8 to 9 km from the Xuxa Pits. 

Sigma said its licences were issued between May 2019 and April 2023, before the community's RTID notices were published in November 2023. It described the licences as vested rights protected under Brazilian law. 

Should the appeals court rule against it, Sigma said it will pursue a further appeal in the superior federal courts. The company noted that Brazil's general election runoff concludes on October 25 and said a decision could be delayed. 

Sigma said it has helped create 19,000 direct and indirect jobs, benefiting about 80,000 people across 12 municipalities in the Vale do Jequitinhonha. Its programs include microcredit for more than 2,000 women entrepreneurs, 1,400 rainwater reservoirs for small farmers, drinking water access for its neighbouring community, and school projects serving about 776 children. 

In post-hoc analyses of ATTAIN-1, Foundayo 17.2 mg was associated with a predicted 57% and 18% reduction in risk of type 2 diabetes and cardiovascular disease vs. placebo

Combined with recent research on the savings tied to weight loss, these findings suggest Foundayo could help reduce long-term spending for patients and healthcare systems

, /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY), the maker of Zepbound (tirzepatide), today announced results from post-hoc analyses of ATTAIN-1 showing that Foundayo was associated with significant reductions in predicted 10-year risk of type 2 diabetes and cardiovascular disease in adults with obesity or overweight with a weight-related medical problem. Obesity is strongly associated with an increased risk of developing both cardiovascular disease and type 2 diabetes.1 Through its proven benefit in weight loss and its ability to improve certain cardiovascular risk factors like blood sugar, blood pressure and cholesterol, Foundayo may be a meaningful treatment option for the more than 100 million U.S. adults living with obesity.2 The findings of these analyses were published in Diabetes, Obesity and Metabolism.

"For many people living with obesity or overweight, the concern isn't just what the scale says today, it's whether their future could include type 2 diabetes or heart disease," said Thomas Seck, M.D., senior vice president of product development, Lilly Cardiometabolic Health. "These additional analyses of ATTAIN-1 show that Foundayo was associated with a lower predicted long-term risk of both conditions, in addition to meaningful weight loss. We've also seen evidence that treating obesity and reducing the risk of its downstream consequences, like cardiovascular disease and type 2 diabetes, can meaningfully lower healthcare costs.3,4,5 That gives us real optimism about what long-term Foundayo use could mean, both for patients and for the broader healthcare system."

In these analyses, modeling showed that Foundayo was associated with clinically meaningful improvements in predicted 10-year risk of type 2 diabetes and cardiovascular disease across all three doses.6 At 72 weeks, participants taking Foundayo 5.5 mg, 9 mg and 17.2 mg showed an estimated 45.0%, 50.0% and 57.0% reduction, respectively, in predicted type 2 diabetes risk versus placebo.7,8 Participants taking Foundayo 17.2 mg also showed an estimated 18.0% reduction in predicted cardiovascular disease risk versus placebo.

ATTAIN-1 Post-Hoc Analyses: Change in Predicted 10-Year Cardiometabolic Risk at 72 Weeks

Foundayo
5.5 mg

Foundayo
9 mg

Foundayo
17.2 mg

Placebo

Type 2 diabetes riski

Predicted 10-year type 2
diabetes risk at baseline

16.4 %

16.0 %

17.1 %

17.3 %

Change in predicted 10-year
type 2 diabetes risk at 72
weeks

-8.0 %

-8.8 %

-9.8 %

-1.7 %

Estimated type 2 diabetes risk
reduction vs. placeboii

45%

(HR = 0.55)

(95% CI 0.52, 0.60)

50%

(HR = 0.50)

(95% CI 0.47, 0.54)

57%

(HR = 0.43)

(95% CI 0.40, 0.47)

–

Cardiovascular disease riskiii

Predicted 10-year
cardiovascular disease risk at
baseline

8.5 %

8.5 %

8.7 %

8.9 %

Change in predicted 10-year
cardiovascular disease risk at
72 weeks

-0.6 %

-0.7 %

-1.0 %

0.6 %

Estimated cardiovascular
disease risk reduction vs.
placeboii

13%

(HR = 0.87)

(95% CI 0.83, 0.90)

15%

(HR = 0.85)

(95% CI 0.82, 0.89)

18%

(HR = 0.82)

(95% CI 0.79, 0.86)

–

iType 2 diabetes risk was estimated using the Cardiometabolic Disease Staging (CMDS) risk engine.

iiEstimated risk reduction versus placebo is approximated based on the model-based hazard ratio (HR); placebo was the reference group. 

iiiCardiovascular disease risk was estimated using the BMI-based Framingham risk engine. 

About Foundayo
Foundayo (orforglipron) is FDA-approved for adults with obesity, or some adults with overweight who also have weight-related medical problems to reduce excess body weight and maintain weight reduction long term, alongside a reduced-calorie diet and increased physical activity. Foundayo is a once-daily small molecule (non-peptide) oral glucagon-like peptide-1 receptor agonist that can be taken any time of the day without restrictions on food and water intake. Orforglipron was discovered by Chugai Pharmaceutical Co., Ltd. and licensed by Lilly in 2018. In addition to chronic weight management, orforglipron is being studied as a potential treatment for type 2 diabetes, obstructive sleep apnea, osteoarthritis knee pain, hypertension, peripheral artery disease and stress urinary incontinence.

About ATTAIN-1 and the ATTAIN clinical trial program  
ATTAIN-1 (NCT05869903) is a Phase 3, 72-week, randomized, double-blind, placebo-controlled trial comparing the efficacy and safety of Foundayo 5.5 mg, 9 mg and 17.2 mg as a monotherapy to placebo in adults with obesity, or overweight with at least one of the following comorbidities: hypertension, dyslipidemia, obstructive sleep apnea or cardiovascular disease, who did not have diabetes. The trial is the first Phase 3 study of this patient population in which treatment was evaluated as an adjunct to exercise and a balanced, healthy diet rather than a reduced-calorie diet. The trial randomized 3,127 participants across the U.S., Brazil, China, India, Japan, South Korea, Puerto Rico, Slovakia, Spain and Taiwan in a 3:3:3:4 ratio to receive either 5.5 mg, 9 mg or 17.2 mg Foundayo or placebo. The primary objective of the study was to demonstrate that Foundayo (5.5 mg, 9 mg or 17.2 mg) is superior to placebo in body weight reduction from baseline after 72 weeks in people with a BMI ≥30.0 kg/m² or a BMI ≥27.0 kg/m² with at least one weight-related comorbidity and a history of at least one self-reported unsuccessful dietary effort to lose body weight.

All participants in the Foundayo treatment arms started the study at a dose of Foundayo 0.8 mg once-daily and then increased the dose in a step-wise approach at four-week intervals to their final randomized maintenance dose of 5.5 mg (via steps at 0.8 mg and 2.5 mg), 9 mg (via steps at 0.8 mg, 2.5 mg and 5.5 mg) or 17.2 mg (via steps at 0.8 mg, 2.5 mg, 5.5 mg, 9 mg and 14.5 mg). The trial was conducted using an investigational formulation of Foundayo at dosages equivalent to Foundayo tablets.

The ATTAIN Phase 3 global clinical development program for orforglipron enrolled more than 4,500 people with obesity or overweight across two global registration trials (ATTAIN-1 & ATTAIN-2).

Endnotes and References

Jensen MD, Ryan DH, Apovian CM, et al. 2013 AHA/ACC/TOS guideline for the management of overweight and obesity in adults. Circulation. 2014;129(25 Suppl 2):S102-S138. Centers for Disease Control and Prevention. Adult Obesity Facts. https://www.cdc.gov/obesity/adult-obesity-facts/index.html. Bjornson AM, Szabo SM, Donato BMK, Gardner M, Kuti E. Costs of obesity, obesity-related complications, and weight loss in the United States: A systematic literature review. J Manag Care Spec Pharm. 2025;31(9):851-861. Xue J, Anderson J, Huang A, Gou R, Sun H, Zhao J, Allende C, Hua H, Hohlbauch A, Chinthammit C. Clinical and Economic Burden of Obesity and Cardiovascular Disease Among Medicare Fee-For-Service Beneficiaries. Diabetes Obes Metab. 2026. Boye KS, Lage MJ, Terrell K. Healthcare outcomes for patients with type 2 diabetes with and without comorbid obesity. J Diabetes Complications. 2020;34(12):107730. D'Agostino Sr RB, Vasan RS, Pencina MJ, Wolf PA, Cobain M, Massaro JM, Kannel WB. General cardiovascular risk profile for use in primary care: the Framingham Heart Study. Circulation. 2008;117(6):743-53. Guo F, Garvey WT. Development of a weighted cardiometabolic disease staging (CMDS) system for the prediction of future diabetes. The Journal of Clinical Endocrinology & Metabolism. 2015;100(10):3871-7. Wilkinson L, Yi N, Mehta T, Judd S, Garvey WT. Development and validation of a model for predicting incident type 2 diabetes using quantitative clinical data and a Bayesian logistic model: a nationwide cohort and modeling study. PLoS medicine. 2020;17(8):e1003232. U.S. FOUNDAYO INDICATION AND SAFETY SUMMARY WITH WARNINGS
Foundayo (fown-DAY-oh) is a prescription medicine used with a reduced-calorie diet and increased physical activity to help adults with obesity, or some adults with overweight who also have weight-related medical problems, to lose excess body weight and keep the weight off.

Foundayo should not be used with other GLP-1 receptor agonist medicines. It is not known if Foundayo is safe and effective for use in children. Warnings – Foundayo may cause tumors in the thyroid, including thyroid cancer. Watch for possible symptoms, such as a lump or swelling in the neck, hoarseness, trouble swallowing, or shortness of breath. If you have any of these symptoms, tell your healthcare provider.

Do not use Foundayo if you or any of your family have ever had a type of thyroid cancer called medullary thyroid carcinoma (MTC). Do not use Foundayo if you have Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). Do not use Foundayo if you have had a serious allergic reaction to orforglipron or any of the ingredients in Foundayo. Foundayo may cause serious side effects, including:

Inflammation of the pancreas (pancreatitis). Stop taking Foundayo and call your healthcare provider right away if you have severe pain in your stomach area (abdomen) that will not go away, with or without nausea or vomiting. Sometimes you may feel the pain from your abdomen to your back.

Severe stomach problems. Stomach problems, sometimes severe, have been reported in people who use Foundayo. Tell your healthcare provider if you have stomach problems that are severe or will not go away.

Dehydration leading to kidney problems. Diarrhea, nausea, and vomiting may cause a loss of fluids (dehydration), which may cause kidney problems. It is important for you to drink fluids to help reduce your chance of dehydration. Tell your healthcare provider right away if you have nausea, vomiting, or diarrhea that does not go away.

Low blood sugar (hypoglycemia). Your risk for getting low blood sugar may be higher if you use Foundayo with medicines that can cause low blood sugar, such as an insulin or sulfonylurea. Signs and symptoms of low blood sugar may include dizziness or light-headedness, sweating, confusion or drowsiness, headache, blurred vision, slurred speech, shakiness, fast heartbeat, anxiety, irritability, mood changes, hunger, weakness, or feeling jittery.

Serious allergic reactions. Stop using Foundayo and get medical help right away if you have any symptoms of a serious allergic reaction, including swelling of your face, lips, tongue or throat, problems breathing or swallowing, severe rash or itching, fainting or feeling dizzy, or very rapid heartbeat.

Changes in vision in patients with type 2 diabetes. Tell your healthcare provider if you have changes in vision during treatment with Foundayo.

Gallbladder problems. Gallbladder problems have happened in some people who use Foundayo. Tell your healthcare provider right away if you get symptoms of gallbladder problems, which may include pain in your upper stomach (abdomen), fever, yellowing of skin or eyes (jaundice), or clay-colored stools.

Food or liquid getting into the lungs during surgery or other procedures that use anesthesia or deep sleepiness (deep sedation). Foundayo may increase the chance of food getting into your lungs during surgery or other procedures. Tell your healthcare providers that you are taking Foundayo before you are scheduled to have surgery or other procedures.

Common side effects
The most common side effects of Foundayo include nausea, constipation, diarrhea, vomiting, indigestion, stomach (abdominal) pain, headache, swollen belly, feeling tired, belching, heartburn, gas, and hair loss. These are not all the possible side effects of Foundayo. Talk to your healthcare provider about any side effect that bothers you or doesn't go away.

Tell your doctor if you have any side effects. You can report side effects at 1-800-FDA-1088 or www.fda.gov/medwatch.

Before taking Foundayo

Tell your healthcare provider about all the medicines you take. Foundayo may affect the way some medicines work, and some medicines may affect the way Foundayo works. Pregnancy Exposure Registry: There will be a pregnancy exposure registry for women who have taken Foundayo during pregnancy. The purpose of this registry is to collect information about the health of you and your baby. Talk to your healthcare provider about how you can take part in this registry, or you may contact Eli Lilly and Company at 1-800-LillyRx (1-800-545-5979). If you take birth control pills by mouth, talk to your healthcare provider before you take Foundayo. Birth control pills may not work as well while taking Foundayo. Your healthcare provider may recommend another type of birth control for 30 days after starting Foundayo and for 30 days after each dose increase of Foundayo. Talk to your healthcare provider about low blood sugar and how to manage it. Tell your healthcare provider if you are taking medicines to treat diabetes including an insulin or sulfonylurea. Review these questions with your healthcare provider:
❑  Do you have other medical conditions, including problems with your pancreas or kidneys, or severe problems with your liver, severe problems with your stomach, such as slowed emptying of your stomach (gastroparesis) or problems digesting food?
❑  Do you have a history of diabetic retinopathy?
❑  Are you scheduled to have surgery or other procedures that use anesthesia or deep sleepiness (deep sedation)?
❑  Are you pregnant or plan to become pregnant? Foundayo may harm your unborn baby.
❑  Are you breastfeeding or plan to breastfeed? Breastfeeding is not recommended during treatment with Foundayo.
❑  Do you take any other prescriptions or over-the-counter medicines, vitamins, or herbal supplements?

How to take

Take Foundayo exactly as your healthcare provider tells you to. Use Foundayo with a reduced-calorie diet and increased physical activity. Take Foundayo by mouth 1 time each day, with or without food. Swallow tablets whole. Do not break, crush, or chew the tablet. If you miss a dose, take it as soon as possible. Do not take 2 doses of Foundayo in the same day. Do not take more than 1 tablet per day. If you miss taking Foundayo for 7 or more days in a row, call your healthcare provider to talk about how to restart your treatment. If you take too much Foundayo, call your healthcare provider or Poison Help line at 1-800-222-1222 or go to the nearest hospital emergency room right away. Learn more
Foundayo is a prescription medicine available in 0.8 mg, 2.5 mg, 5.5 mg, 9 mg, 14.5 mg, or 17.2 mg oral tablets. For more information, call 1-800-545-5979 or go to foundayo.lilly.com.

This summary provides basic information about Foundayo but does not include all information known about this medicine. Read the information that comes with your prescription each time your prescription is filled. This information does not take the place of talking with your doctor. Be sure to talk to your doctor or other healthcare provider about Foundayo and how to take it. Your doctor is the best person to help you decide if Foundayo is right for you.

OG CON BS APR2026

Foundayo™ is a trademark of Eli Lilly and Company.

U.S. ZEPBOUND INDICATIONS AND SAFETY SUMMARY WITH WARNINGS

Zepbound® (ZEHP-bownd) is an injectable prescription medicine used with a reduced-calorie diet and increased physical activity to help adults with:

obesity, or some adults with overweight who also have weight-related medical problems, to lose excess body weight and keep the weight off. moderate-to-severe obstructive sleep apnea (OSA) and obesity to improve their OSA. Zepbound contains tirzepatide and should not be used with other tirzepatide-containing products or any GLP-1 receptor agonist medicines. It is not known if Zepbound is safe and effective for use in children.

Warnings - Zepbound may cause tumors in the thyroid, including thyroid cancer. Watch for possible symptoms, such as a lump or swelling in the neck, hoarseness, trouble swallowing, or shortness of breath. If you have any of these symptoms, tell your healthcare provider.

Do not use Zepbound if you or any of your family have ever had a type of thyroid cancer called medullary thyroid carcinoma (MTC). Do not use Zepbound if you have Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). Do not use Zepbound if you have had a serious allergic reaction to tirzepatide or any of the ingredients in Zepbound. KwikPen®: Do not share your KwikPen with other people, even if the pen needle has been changed.  You may give other people a serious infection or get a serious infection from them.

Zepbound may cause serious side effects, including:

Severe stomach problems. Stomach problems, sometimes severe, have been reported in people who use Zepbound. Tell your healthcare provider if you have stomach problems that are severe or will not go away.

Dehydration leading to kidney problems. Diarrhea, nausea, and vomiting may cause a loss of fluids (dehydration), which may cause kidney problems. It is important for you to drink fluids to help reduce your chance of dehydration. Tell your healthcare provider right away if you have nausea, vomiting, or diarrhea that does not go away.

Gallbladder problems. Gallbladder problems have happened in some people who use Zepbound. Tell your healthcare provider right away if you get symptoms of gallbladder problems, which may include pain in your upper stomach (abdomen), fever, yellowing of skin or eyes (jaundice), or clay-colored stools.

Inflammation of the pancreas (pancreatitis). Stop using Zepbound and call your healthcare provider right away if you have severe pain in your stomach area (abdomen) that will not go away, with or without nausea or vomiting. You may feel the pain from your abdomen to your back.

Serious allergic reactions. Stop using Zepbound and get medical help right away if you have any symptoms of a serious allergic reaction, including swelling of your face, lips, tongue or throat, problems breathing or swallowing, severe rash or itching, fainting or feeling dizzy, or very rapid heartbeat.

Low blood sugar (hypoglycemia). Your risk for getting low blood sugar may be higher if you use Zepbound with medicines that can cause low blood sugar, such as a sulfonylurea or insulin. Signs and symptoms of low blood sugar may include dizziness or light-headedness, sweating, confusion or drowsiness, headache, blurred vision, slurred speech, shakiness, fast heartbeat, anxiety, irritability, mood changes, hunger, weakness or feeling jittery.

Changes in vision in patients with type 2 diabetes. Tell your healthcare provider if you have changes in vision during treatment with Zepbound.

Food or liquid getting into the lungs during surgery or other procedures that use anesthesia or deep sleepiness (deep sedation). Zepbound may increase the chance of food getting into your lungs during surgery or other procedures. Tell all your healthcare providers that you are taking Zepbound before you are scheduled to have surgery or other procedures.

Common side effects

The most common side effects of Zepbound include nausea, diarrhea, vomiting, constipation, stomach (abdominal) pain, indigestion, injection site reactions, feeling tired, allergic reactions, belching, hair loss, and heartburn. These are not all the possible side effects of Zepbound. Talk to your healthcare provider about any side effect that bothers you or doesn't go away.

Tell your doctor if you have any side effects. You can report side effects at 1-800-FDA-1088 or www.fda.gov/medwatch.

Before using Zepbound

Your healthcare provider should show you how to use Zepbound before you use it for the first time. Talk to your healthcare provider about low blood sugar and how to manage it. Tell yourhealthcare provider if you are taking medicines to treat diabetes including an insulin or sulfonylurea.  If you take birth control pills by mouth, talk to your healthcare provider before you use Zepbound. Birth control pills may not work as well while using Zepbound. Your healthcare provider may recommend another type of birth control for 4 weeks after you start Zepbound and for 4 weeks after each increase in your dose of Zepbound. Review these questions with your healthcare provider:
❑ Do you have other medical conditions, including problems with your pancreas, or severe problems with your stomach, such as slowed emptying of your stomach (gastroparesis) or problems digesting food?
❑ Do you take diabetes medicines, such as insulin or sulfonylureas?
❑ Do you have a history of diabetic retinopathy?
❑ Are you scheduled to have surgery or other procedures that use anesthesia or deep sleepiness (deep sedation)?
❑ Do you take any other prescription medicines or over-the-counter drugs, vitamins, or herbal supplements?
❑ Are you pregnant, plan to become pregnant, breastfeeding, or plan to breastfeed? Zepbound may harm your unborn baby. Tell your healthcare provider if you become pregnant while using Zepbound. Zepbound may pass into your breast milk. You should talk with your healthcare provider about the best way to feed your baby while using Zepbound.

Pregnancy Exposure Registry: There is a pregnancy exposure registry for women who have taken Zepbound during pregnancy. The purpose of this registry is to collect information about the health of you and your baby. Talk to your healthcare provider about how you can take part in this registry, or you may call 1-844-524-0039 or email at [email protected] or visit https://pregnancyregistry.lilly.com/zepbound. How to take

Read the Instructions for Use that come with Zepbound. Use Zepbound exactly as your healthcare provider says. Use Zepbound with a reduced-calorie diet and increased physical activity. Inject Zepbound under the skin (subcutaneously) of your stomach (abdomen), thigh, or
have another person inject in the back of the upper arm. Do not inject ZEPBOUND into a muscle (intramuscularly) or vein (intravenously). Use Zepbound 1 time each week, at any time of the day. Change (rotate) your injection site with each weekly injection. Do not use the same site for each injection. If you take too much Zepbound, call your healthcare provider, call the Poison Help line at 1-800-222-1222 or go to the nearest hospital emergency room right away.

Zepbound is approved as a 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, and 15 mg injection.

Learn more
Zepbound is a prescription medicine. For more information, call 1-800-LillyRx (1-800-545-5979) or go to www.zepbound.lilly.com.

This summary provides basic information about Zepbound but does not include all information known about this medicine. Read the information that comes with your prescription each time your prescription is filled. This information does not take the place of talking with your healthcare provider. Be sure to talk to your healthcare provider about Zepbound and how to take it. Your healthcare provider is the best person to help you decide if Zepbound is right for you.

ZP CON BS 01SEP2026

Zepbound®, its delivery device base and KwikPen® are registered trademarks owned or licensed by Eli Lilly and Company, its subsidiaries, or affiliates.

About Lilly   
Lilly is a medicine company turning science into healing to make life better for people around the world. We've been pioneering life-changing discoveries for 150 years, and today our medicines help tens of millions of people across the globe. Harnessing the power of biotechnology, chemistry and genetic medicine, our scientists are urgently advancing new discoveries to solve some of the world's most significant health challenges: redefining diabetes care; treating obesity and curtailing its most devastating long-term effects; advancing the fight against Alzheimer's disease; providing solutions to some of the most debilitating immune system disorders; and transforming the most difficult-to-treat cancers into manageable diseases. With each step toward a healthier world, we're motivated by one thing: making life better for millions more people. That includes delivering innovative clinical trials that reflect the diversity of our world and working to ensure our medicines are accessible and affordable. To learn more, visit Lilly.com and Lilly.com/news, or follow us on Facebook, Instagram, and LinkedIn. P-LLY

Trademarks and Trade Names
All trademarks or trade names referred to in this press release are the property of the company, or, to the extent trademarks or trade names belonging to other companies are referenced in this press release, the property of their respective owners. Solely for convenience, the trademarks and trade names in this press release are referred to without the ® and ™ symbols, but such references should not be construed as any indicator that the company or, to the extent applicable, their respective owners will not assert, to the fullest extent under applicable law, the company's or their rights thereto. We do not intend the use or display of other companies' trademarks and trade names to imply a relationship with, or endorsement or sponsorship of us by, any other companies. 

Cautionary Statement Regarding Forward-Looking Statements  
This press release contains forward-looking statements (as that term is defined in the Private Securities Litigation Reform Act of 1995) about Foundayo (orforglipron) as a potential treatment for adults with obesity, and reflects Lilly's current beliefs and expectations. However, as with any pharmaceutical product, there are substantial risks and uncertainties in the process of drug research, development, and commercialization. Among other things, there is no guarantee that planned or ongoing studies will be completed as planned, that future study results will be consistent with study results to date, that Foundayo will receive additional regulatory approvals, or that Lilly will execute its strategy as expected. For further discussion of these and other risks and uncertainties that could cause actual results to differ from Lilly's expectations, see Lilly's Form 10-K and Form 10-Q filings with the United States Securities and Exchange Commission. Except as required by law, Lilly undertakes no duty to update forward-looking statements to reflect events after the date of this release.  

SOURCE Eli Lilly and Company

Microsoft má za sebou nejsilnější čtvrtletí od konce 90. let a podle řady analytiků ještě zdaleka nemusí být na konci růstového příběhu. Wall Street u něj očekává dvouciferný růst tržeb i zisků a většina analytiků věří, že AI strategie společnosti v čele s produktem Copilot je teprve na začátku svého komerčního potenciálu.

Pokračování článku je dostupné jen klientům placených služeb Patria Plus / Investor Plus případně uživatelům platformy Patria Direct. Pokud jste klientem těchto služeb, potom je nutné se Přihlásit.

V rámci placeného informačního servisu získáte přístup ke kompletnímu zpravodajství www.patria.cz bez jakýchkoliv omezení. Veškeré zprávy, komentáře a horké zprávy jsou zobrazovány terminálovou metodou (bez nutnosti obnovovat stránku) bez zpoždění a v plné verzi.

Nejen zpravodajství, ale i další služby získáte v Patria Plus / Investor Plus - sms a e-mailové zpravodajství, data z finančních trhů v reálném čase, kompletní analytický servis, rozsáhlé databáze časových řad ke stažení, prognózy vývoje a valuace, ekonomické fundamenty, nástroje a kalkulátory... více

NIKE, Inc. (NKE) Q1 2027 Earnings Call October 1, 2026 5:00 PM EDT

Company Participants

Paul Trussell - VP & Treasurer
Elliott Hill - CEO, President & Director
David Denton - Executive VP, CFO, Interim Corporate Controller & Principal Accounting Officer

Conference Call Participants

Simeon Siegel - Guggenheim Securities, LLC, Research Division
Brooke Roach - Goldman Sachs Group, Inc., Research Division
Jay Sole - UBS Investment Bank, Research Division
Robert Drbul - BTIG, LLC, Research Division
Samuel Poser - Williams Trading, LLC, Research Division
Alexandra Straton - Morgan Stanley, Research Division
Matthew Boss - JPMorgan Chase & Co, Research Division
Michael Binetti - Evercore ISI Institutional Equities, Research Division

Presentation

Operator

Good afternoon, everyone, and welcome to NIKE, Inc.'s First Quarter Fiscal 2027 Conference Call. For those who want to reference today's press release, you'll find it at investors.nike.com.

Leading today's call is Paul Trussell, VP of Corporate Finance and Treasurer. I'd now like to turn the call over to Paul Trussell.

Paul Trussell
VP & Treasurer

Thank you, operator. Hello, everyone, and thank you for joining us today to discuss NIKE, Inc.'s First Quarter Fiscal 2027 results. Joining us on today's call will be NIKE, Inc. President and CEO, Elliott Hill; and CFO, Dave Denton.

Before we begin, let me remind you that participants on this call will make forward-looking statements based on current expectations, and those statements are subject to certain risks and uncertainties that could cause actual results to differ materially. These risks and uncertainties are detailed in NIKE's reports filed with the SEC. In addition, participants may discuss non-GAAP financial measures and nonpublic financial and statistical information. Please refer to NIKE's earnings press release or NIKE's website, investors.nike.com, for comparable GAAP measures and quantitative reconciliations.

All growth comparisons on the call today are presented on a year-over-year basis and are currency neutral unless

McKesson (MCK +5.27%) investors received a strong dose of good news on the second-to-last trading day of the week. The storied pharmaceutical and healthcare products distributor announced the extension of its partnership with a major pharmacy chain operator. This development pushed McKesson stock to an over 5% gain on Thursday.

Long-standing partnershipMcKesson's counterparty is none other than the ubiquitous CVS Health (CVS -0.57%). The two companies have signed an agreement in principle for the former to distribute medicines to mail-order, specialty, and retail pharmacies, as well as distribution centers, through June 2032.

Image source: Getty Images.

In the press release trumpeting the new arrangement, McKesson quoted CEO Brian Tyler as saying that "We are pleased to extend our long-standing, strategic relationship with CVS Health and continue supporting their important role in serving patients and communities across the country."

McKesson didn't hesitate to mention that the extension builds on a 25-year history between it and CVS.

Premium Feature

Moneyball Superscore

84/100

Today's Change

(

5.27

%) $

45.01

Current Price

$

898.82

Guidance maintainedWith one important item ticked off its to-do list, McKesson was confident enough to reiterate its guidance for the current fiscal year (2027). It' still believes its net income not under generally accepted accounting principles (non-GAAP, or adjusted) will hit $44.20 to $45 per share. The company also reaffirmed its long-term forecast of 13% to 16% growth in adjusted, per-share earnings.

McKesson is a go-to distributor in its field, a longtime operator that many partners trust to get medicines and other supplies where they need to go. That's a solid advantage in an environment where the U.S. population is aging proportionally, thereby requiring more medical care and products. The company's stock is a fine play on this dynamic.

Eric Volkman has no position in any of the stocks mentioned. The Motley Fool recommends CVS Health and McKesson. The Motley Fool has a disclosure policy.

Nike is staring down its worst stock performance in decades while rivals steal its customers and its own earnings hide a financial lifeline most investors missed. LeBron James thinks he knows exactly where the brand went wrong.

This post may contain links from our sponsors and affiliates, and Flywheel Publishing may receive compensation for actions taken through them.

LeBron James still moves money for whoever he plays for. After he joined the Philadelphia 76ers, the team’s ticket sales on StubHub (NYSE:STUB | STUB Price Prediction) jumped 585%, and the Sixers drew 38% of all NBA ticket search traffic. Nike (NYSE:NKE) has paid him since 2003, and it heads into tonight’s earnings report in much worse shape.

Nike traded at $35.09 late Thursday. That leaves the stock down 43.46% year to date and 48.01% over the past 12 months. CNBC reported that Nike is on track for its worst year since 1993, the year Michael Jordan first retired.

LeBron’s Fix Goes Straight to What Nike Lost At the CNBC Sport x Boardroom Game Plan Summit on July 16, Boardroom’s Rich Kleiman asked James how Nike could recover:

“You’ve got to get back into the roots. You’ve got to get back to being out in the inner city, having runners. When I was coming up, you had people who were literally out in the communities talking to these younger generations, asking them what they like, what they don’t like.”

He ended with a warning:

“It was such a cool factor. So we can’t lose our cool.”

On Thursday, CNBC paired the clip with Wharton marketing professor Americus Reed, who argued that Nike leaned too hard on direct-to-consumer channels and celebrity deals while letting community relationships slip. A sellout shoe is a transaction; loyalty is separate. Pulling back from retail stores removed the emotion and storytelling that build deeper bonds with shoppers. Reed’s point: a brand “has to live and breathe within the community.”

Nike’s Recent Profits Lean on a Tariff Refund In its June 30 report, Nike posted revenue of $10.97 billion, down 1.1% from a year earlier. Diluted EPS came in at $0.72, but $0.52 of that came from a $986 million tariff-recovery benefit. Without the refund, full-year EPS would have been $1.58. Digital sales fell 12%, Greater China dropped 17% on a currency-neutral basis, and Converse sank 32%.

CEO Elliott Hill named the weakest spots:

“We know we’re not living up to our full potential, particularly in Nike Sportswear and Jordan Streetwear, where sell-through remains challenged.”

Sportswear and Jordan Streetwear make up about half of Nike’s revenue. Running is strongest, with five consecutive quarters of double-digit growth. Hill: “When we lead with sport, we win.”

Rivals Reed Named Are Taking Share Reed singled out Hoka and On Holding (NYSE:ONON) as the brands winning shoppers’ attention. On Holding grew Q2 2026 revenue 13.49%, or 21.6% in constant currency. Its gross margin reached 65.4%, and direct sales rose 26.0%. On Holding also signed Kylian Mbappé away from Nike as it moves into soccer. Co-CEO David Allemann described the strategy:

“We are proving that a brand can achieve global scale without compromising its premium brand positioning.”

At Deckers Outdoor (NYSE:DECK), Hoka’s net sales rose 7.7% to $703.50 million, and gross margin came in at 56.4%. Nike’s full-year gross margin, excluding the tariff benefit, was 40.8%.

What to Watch After the Bell Management guided for revenue to fall by a low to mid-single digits percentage. CFO Matt Friend said “profitability will bottom before sales” in China. Analysts are conservative: 25 rate the stock a hold, with a $45.63 price target. Watch whether sell-through improves in Sportswear and Jordan, and whether running’s momentum spreads to basketball. Hill warned that “progress will continue to be uneven.”

Data Sources CNBC: Wharton’s Americus Reed on Nike: Reed’s view on transactions versus loyalty, the effect of direct-to-consumer, and the worst-year-since-1993 comparison. Contact [email protected] for any questions or corrections.

The pilots of a ​Miami-based 21 Air cargo plane operating for Amazon.com that crashed in Miami last month killing ‌five people, were unaware of wind conditions, the National Transportation Safety Board said on Thursday.

The NTSB's preliminary report is the first detailed account of the September 6 crash and points to a series of likely failures — from excessive speed and unused braking systems to ​missing wind information from an air traffic controller — that may have led to one of the deadliest ​US runway accidents in years.

The 21 Air-operated cargo flight for Amazon Air, which is Amazon's ⁠cargo logistics network, overran a runway while landing at Miami International Airport and struck two vehicles on the ground. ​Amazon has since paused use of 21 Air.

The NTSB said a Federal Aviation Administration air traffic controller issued a ​landing clearance, but did not provide information on the wind as required by the FAA.

About four minutes before issuing the landing clearance, when asked by another flight for wind information, the controller stated winds were from 190° at 19 knots with gusts to 22 knots. The 21 ​Air flight was not on the radio frequency at the time, the NTSB said.

The FAA did not immediately comment.

The ​aircraft was a 32-year-old Boeing (BA.N) 767-300 freighter that had previously operated as a passenger jet for various airlines from 1994 to ‌2015.

The NTSB ⁠said the captain of the 21 Air-operated plane considered aborting the landing after the aircraft touched down, citing evidence from a flight data recorder.

The NTSB said the first officer cautioned the captain they were flying "too fast" just over a minute before touching down on the runway that they overran and made additional comments about the airplane’s excessive speed.

The ​NTSB said the captain did ​not verbally acknowledge all ⁠of the first officer's comments about speed. The NTSB said data showed the speed brakes remained stowed and the thrust reversers did not deploy during the landing.

The airplane touched ​down about 3,750 feet (1143 meter) past the start of the runway at a groundspeed ​of 160 knots (184mph).

The ⁠cargo plane was on its third flight of the day, coming from San Juan, Puerto Rico. It had flown from Cincinnati to Miami and from Miami to San Juan earlier before the crash.

Amazon said it remains committed to supporting the ⁠NTSB’s ongoing ​investigation.

21 Air said its "executive leadership team is actively engaged in managing operational ​risk and fostering a culture of accountability and continuous improvement."

The company added it is reviewing the NTSB preliminary report and "will take all appropriate ​action to improve our safety based on the facts as they are established.”

SummaryNike enters FY27 with worsening fundamentals: revenue shrinking, China collapsing, wholesale relying on costly retailer working capital, and margins at risk despite temporary logistics relief.Q1 FY27 shows accelerating deterioration: China is down 22%, Converse is down 28%, EPS reset 25% below expectations, and management is guiding high‑single‑digit revenue declines for the full year.Valuation remains stretched at 27x guided EPS, dividend payout hits 131%, $2B debt maturity looms, and multiple compression points to a clear path toward $30 or even $25.Looking for a helping hand in the market? Members of iREIT®+HOYA Capital get exclusive ideas and guidance to navigate any climate. Learn More » ozgurdonmaz/iStock Unreleased via Getty Images

Introduction Three months ago, I wrote that at a share price of $40 for Nike (NKE) still wasn't cheap. Entering its earnings report, the stock was down 15% to $35.21, its 52-week low. While the brand is surely valuable, I pointed out that the

8.48K Followers

Analyst’s Disclosure: I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.

Caterpillar (CAT - Free Report) closed the most recent trading day at $826.35, moving +1.92% from the previous trading session. This move outpaced the S&P 500's daily gain of 0.2%. Meanwhile, the Dow gained 0.04%, and the Nasdaq, a tech-heavy index, added 0.04%.

Heading into today, shares of the construction equipment company had gained 2.34% over the past month, outpacing the Industrial Products sector's loss of 0.74% and the S&P 500's loss of 0.35%.

The investment community will be closely monitoring the performance of Caterpillar in its forthcoming earnings report. The company is predicted to post an EPS of $6.95, indicating a 40.4% growth compared to the equivalent quarter last year. Meanwhile, the latest consensus estimate predicts the revenue to be $20.19 billion, indicating a 14.47% increase compared to the same quarter of the previous year.

For the annual period, the Zacks Consensus Estimates anticipate earnings of $27.37 per share and a revenue of $79.37 billion, signifying shifts of +43.6% and +17.43%, respectively, from the last year.

Investors might also notice recent changes to analyst estimates for Caterpillar. Recent revisions tend to reflect the latest near-term business trends. Therefore, positive revisions in estimates convey analysts' confidence in the business performance and profit potential.

Based on our research, we believe these estimate revisions are directly related to near-term stock moves. To take advantage of this, we've established the Zacks Rank, an exclusive model that considers these estimated changes and delivers an operational rating system.

The Zacks Rank system ranges from #1 (Strong Buy) to #5 (Strong Sell). It has a remarkable, outside-audited track record of success, with #1 stocks delivering an average annual return of +25% since 1988. Within the past 30 days, our consensus EPS projection has moved 0.09% higher. Caterpillar is currently sporting a Zacks Rank of #1 (Strong Buy).

Investors should also note Caterpillar's current valuation metrics, including its Forward P/E ratio of 29.62. This expresses a premium compared to the average Forward P/E of 17.81 of its industry.

It is also worth noting that CAT currently has a PEG ratio of 1.41. The PEG ratio is similar to the widely-used P/E ratio, but this metric also takes the company's expected earnings growth rate into account. The Manufacturing - Construction and Mining industry currently had an average PEG ratio of 1.25 as of yesterday's close.

The Manufacturing - Construction and Mining industry is part of the Industrial Products sector. This industry currently has a Zacks Industry Rank of 82, which puts it in the top 34% of all 250+ industries.

The strength of our individual industry groups is measured by the Zacks Industry Rank, which is calculated based on the average Zacks Rank of the individual stocks within these groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.

Ensure to harness Zacks.com to stay updated with all these stock-shifting metrics, among others, in the next trading sessions.

The divestment of a majority stake in a legacy business was the factor lifting Thomson Reuters (TRI +2.09%) stock above many others on Thursday. With that tailwind at its back, the business-focused media company's stock rose by more than 2% that trading session, on a day when the bellwether S&P 500 index only crept up by 0.2%.

Done dealThat morning, Thomson Reuters announced that it had closed the sale of a 51% stake in its global print unit. The buyers are what the company described as "capital accounts," advised by the veteran private equity firm KKR (KKR -0.07%).

Image source: Getty Images.

Following the sale, the newly named Westbridge Print will operate as a joint venture, with Thomson Reuters retaining a minority stake. Westbridge will concentrate on publications for legal and tax professionals. It will also offer commercial printing services for book publishers.

The move is an attempt to narrow Thomson Reuters' focus on next-generation, artificial intelligence (AI) solutions targeting industries it has served for years. Namely, these are the tax, audit, compliance, and legal fields.

The company did not provide any financial details of the transaction in its announcement. However, when originally divulging the sale in July, it said KKR would pay roughly $500 million.

Today's Change

(

2.09

%) $

2.03

Current Price

$

99.36

The future of specialty mediaThomson Reuters is clearly determined to push hard into next-generation offerings for its relatively affluent client base. This strategy depends on being tech-forward, so shedding large stakes in legacy operations like print media makes a great deal of sense.

So we should consider this to be good news from Thomson Reuters, and a sure sign that it's executing on an important objective.

Eric Volkman has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends KKR. The Motley Fool recommends Thomson Reuters. The Motley Fool has a disclosure policy.

Expansion Recognizes the Strength of PECO’s Operating Platform while Generating Capital for PECO to Acquire Properties with Strong Growth Profiles  | Source: Phillips Edison & Company, Inc.

CINCINNATI , Oct. 01, 2026 (GLOBE NEWSWIRE) -- Phillips Edison & Company, Inc. (Nasdaq: PECO) (“PECO”), one of the nation’s largest owners and operators of high-quality, grocery-anchored neighborhood shopping centers, today announced an amended and restated joint venture partnership with Northwestern Mutual, one of the largest commercial real estate mortgage and equity investors in the U.S., which extends the term of the venture, Grocery Retail Partners I LLC (“GRP I”), by 10 years to 2036.

The expanded joint venture will acquire 13 high-quality, grocery-anchored shopping centers currently owned and operated by PECO across eight states. The portfolio is valued at approximately $377.5 million. Northwestern Mutual and PECO will retain approximately 86% and 14% interest in the joint venture, respectively. PECO will continue to provide leasing, asset management and property management services for the joint venture, in addition to earning recurring fees related to these services. The expansion creates incremental investment capacity for PECO to fund future acquisitions, development and redevelopment opportunities.

Jeff Edison, Chairman and Chief Executive Officer of PECO, stated: “Expanding our partnership with Northwestern Mutual, one of the country’s largest and most experienced commercial real estate investors, demonstrates continued institutional demand for high-quality, grocery-anchored shopping centers.”

The 13 assets are located in suburban neighborhoods and are merchandised with a strong line-up of necessity-based goods and services, including dominant grocers, restaurants and medical retail, as well as health, wellness and personal service uses.

Edison added, “In addition to the durable fee revenue generated, this expanded joint venture advances PECO’s capital allocation strategy by monetizing value from high-quality, stabilized assets and redeploying that capital into grocery-anchored and Everyday Retail™ opportunities with strong growth potential. PECO’s joint venture partnerships play a key role in our long-term growth and commitment to delivering stakeholder value. We’re able to do this while maintaining balance sheet strength and a disciplined approach to investing that have always defined PECO.”

The expansion will occur in stages with this initial stage seeding approximately half of the assets into the venture. Additional transfers under the existing agreement are expected to be completed by early 2027, and the timing and composition of future closings may change.

Following the completion of the expanded joint venture, PECO’s unconsolidated joint venture portfolio is expected to include more than 40 shopping centers across 17 states and will be valued at approximately $1.2 billion of assets under management.

About Northwestern Mutual

Northwestern Mutual has been helping people and businesses achieve financial security for more than 165 years. Through a comprehensive planning approach, Northwestern Mutual combines the expertise of its financial professionals with a personalized digital experience and industry-leading products to help its clients plan for what's most important. With more than $780 billion of total assets1 managed across the company's institutional portfolio as well as retail investment client portfolios, more than $40 billion in revenues, and $2.5 trillion worth of life insurance protection in force, Northwestern Mutual delivers financial security to more than five million people with life insurance, disability income insurance, long-term care insurance, annuities, and brokerage and advisory services. Northwestern Mutual ranked 109 on the 2026 FORTUNE 500 and was recognized by FORTUNE® as one of the "World's Most Admired" life insurance companies in 2026.

Learn more at https://www.northwesternmutual.com/.

Northwestern Mutual is the marketing name for The Northwestern Mutual Life Insurance Company (NM), Milwaukee, WI (life and disability insurance, annuities, and life insurance with long-term care benefits) and its subsidiaries. Subsidiaries include Northwestern Mutual Investment Services, LLC (NMIS) (investment brokerage services), broker-dealer, registered investment adviser, member FINRA and SIPC; the Northwestern Mutual Wealth Management Company® (NMWMC) (investment advisory and services), federal savings bank; and Northwestern Long Term Care Insurance Company (NLTC) (long-term care insurance). Not all Northwestern Mutual representatives are advisors. Only those representatives with "Advisor" in their title or who otherwise disclose their status as an advisor of NMWMC are credentialed as NMWMC representatives to provide investment advisory services.

1 Includes investments and separate account assets of Northwestern Mutual as well as retail investment assets held or managed for clients.

About Phillips Edison & Company
Phillips Edison & Company, Inc. (“PECO”) is one of the nation’s largest owners and operators of high-quality, grocery-anchored neighborhood shopping centers. Founded in 1991, PECO has generated strong results through its vertically-integrated operating platform and national footprint of well-occupied shopping centers. PECO’s centers feature a mix of national and regional retailers providing necessity-based goods and services in fundamentally strong markets throughout the United States. PECO’s top grocery anchors include Kroger, Publix, Albertsons and Ahold Delhaize. As of June 30, 2026, PECO managed 330 shopping centers, including 302 wholly-owned centers comprising 33.9 million square feet across 31 states and 28 shopping centers owned in three institutional joint ventures. PECO is focused on creating great grocery-anchored shopping experiences and improving communities, one neighborhood shopping center at a time.

PECO uses, and intends to continue to use, its Investors website, which can be found at https://investors.phillipsedison.com, as a means of disclosing material nonpublic information and for complying with its disclosure obligations under Regulation FD.

Forward-Looking Statements
This press release may contain certain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements can generally be identified by the Company’s use of forward-looking terminology such as “may,” “will,” “expect,” “intend,” “anticipate,” “estimate,” “believe,” “continue,” “seek,” “objective,” “goal,” “strategy,” “plan,” “focus,” “priority,” “should,” “could,” “potential,” “possible,” “look forward,” “optimistic,” “commit,” or other similar words. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. Such statements are subject to known and unknown risks and uncertainties, which could cause actual results to differ materially from those projected or anticipated, including the risk factors and other risks and uncertainties described in the Company’s 2025 Annual Report on Form 10-K, filed with the SEC on February 10, 2026, as updated from time to time in the Company’s periodic and/or current reports filed with the SEC, which are accessible on the SEC’s website at www.sec.gov. Except as required by law, the Company does not undertake any obligation to update or revise any forward-looking statement, whether as a result of new information, future events, or otherwise.

Investors:
Kimberly Green, Head of Investor Relations
(513) 692-3399, [email protected]

In the latest trading session, Sunrun (RUN - Free Report) closed at $7.64, marking a -1.67% move from the previous day. The stock trailed the S&P 500, which registered a daily gain of 0.2%. At the same time, the Dow added 0.04%, and the tech-heavy Nasdaq gained 0.04%.

Prior to today's trading, shares of the solar energy products distributor had lost 13.28% lagged the Oils-Energy sector's loss of 2.32% and the S&P 500's loss of 0.35%.

The upcoming earnings release of Sunrun will be of great interest to investors. In that report, analysts expect Sunrun to post earnings of $0.16 per share. This would mark year-over-year growth of 166.67%. Meanwhile, the latest consensus estimate predicts the revenue to be $773.4 million, indicating a 6.74% increase compared to the same quarter of the previous year.

For the annual period, the Zacks Consensus Estimates anticipate earnings of $1.19 per share and a revenue of $3.12 billion, signifying shifts of -30.41% and +5.49%, respectively, from the last year.

Investors should also pay attention to any latest changes in analyst estimates for Sunrun. These latest adjustments often mirror the shifting dynamics of short-term business patterns. As a result, upbeat changes in estimates indicate analysts' favorable outlook on the business health and profitability.

Our research demonstrates that these adjustments in estimates directly associate with imminent stock price performance. To utilize this, we have created the Zacks Rank, a proprietary model that integrates these estimate changes and provides a functional rating system.

The Zacks Rank system, running from #1 (Strong Buy) to #5 (Strong Sell), holds an admirable track record of superior performance, independently audited, with #1 stocks contributing an average annual return of +25% since 1988. Over the past month, there's been a 0.33% rise in the Zacks Consensus EPS estimate. Sunrun is currently sporting a Zacks Rank of #3 (Hold).

Looking at valuation, Sunrun is presently trading at a Forward P/E ratio of 6.55. This expresses a discount compared to the average Forward P/E of 13.31 of its industry.

The Solar industry is part of the Oils-Energy sector. At present, this industry carries a Zacks Industry Rank of 212, placing it within the bottom 14% of over 250 industries.

The Zacks Industry Rank gauges the strength of our individual industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.

Keep in mind to rely on Zacks.com to watch all these stock-impacting metrics, and more, in the succeeding trading sessions.

In the latest trading session, Eaton (ETN - Free Report) closed at $437.28, marking a +1.76% move from the previous day. This move outpaced the S&P 500's daily gain of 0.2%. Elsewhere, the Dow gained 0.04%, while the tech-heavy Nasdaq added 0.04%.

Coming into today, shares of the power management company had gained 9.94% in the past month. In that same time, the Industrial Products sector lost 0.74%, while the S&P 500 lost 0.35%.

The upcoming earnings release of Eaton will be of great interest to investors. The company is predicted to post an EPS of $3.53, indicating a 14.98% growth compared to the equivalent quarter last year. Our most recent consensus estimate is calling for quarterly revenue of $8.42 billion, up 20.52% from the year-ago period.

For the entire fiscal year, the Zacks Consensus Estimates are projecting earnings of $13.57 per share and a revenue of $32.66 billion, representing changes of +12.43% and +18.98%, respectively, from the prior year.

It is also important to note the recent changes to analyst estimates for Eaton. Such recent modifications usually signify the changing landscape of near-term business trends. As a result, upbeat changes in estimates indicate analysts' favorable outlook on the business health and profitability.

Our research shows that these estimate changes are directly correlated with near-term stock prices. Investors can capitalize on this by using the Zacks Rank. This model considers these estimate changes and provides a simple, actionable rating system.

The Zacks Rank system, spanning from #1 (Strong Buy) to #5 (Strong Sell), boasts an impressive track record of outperformance, audited externally, with #1 ranked stocks yielding an average annual return of +25% since 1988. Over the last 30 days, the Zacks Consensus EPS estimate has witnessed a 0.05% increase. Right now, Eaton possesses a Zacks Rank of #3 (Hold).

Looking at its valuation, Eaton is holding a Forward P/E ratio of 31.68. This represents a premium compared to its industry average Forward P/E of 24.08.

Investors should also note that ETN has a PEG ratio of 2.7 right now. This popular metric is similar to the widely-known P/E ratio, with the difference being that the PEG ratio also takes into account the company's expected earnings growth rate. The Manufacturing - Electronics industry currently had an average PEG ratio of 1.62 as of yesterday's close.

The Manufacturing - Electronics industry is part of the Industrial Products sector. With its current Zacks Industry Rank of 74, this industry ranks in the top 31% of all industries, numbering over 250.

The Zacks Industry Rank assesses the vigor of our specific industry groups by computing the average Zacks Rank of the individual stocks incorporated in the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.

Don't forget to use Zacks.com to keep track of all these stock-moving metrics, and others, in the upcoming trading sessions.

Shares of Nu Holdings (NU +4.98%) have been volatile over the past 12 months. Their 52-week high is 69% higher than the 52-week low (as of Sept. 29). But investors should understand that the wild ups and downs are separate from how the actual business is doing. This is why it's absolutely critical to take a closer look at Nu's financial performance.

Is this fintech stock a millionaire maker?

Image source: Getty Images.

Nu's growth is the driving force Nu's historical performance provides hints of its true potential. The fundamental gains have been nothing short of phenomenal. The company's growth is the most compelling characteristic.

The business raked in $5.9 billion in revenue in Q2 (ended June 30), up 39% year over year on a currency-neutral basis, with net income rising 49%. It added 4 million net new customers during the three months, and it now has 140 million users in total. The vast majority are in Brazil, with Mexico and Colombia growing rapidly.

Management says that Nu is the largest digital banking platform in Latin America. Aided by its focus on technology and data, the company has been targeting the huge unbanked and underbanked population in the region.

Risks come from two obvious sources Deteriorating credit conditions are perhaps the biggest risk factor investors should be mindful of. Of Nu's entire $77.6 billion of credit exposure, 83% is from credit cards, a high-interest and unsecured product. In adverse economic times, customers will likely neglect these payments first.

Nu has a strong position in Latin American banking. But the countries it operates in have their own macro-related risks. Currencies are volatile. Economies are still emerging. Inflation can be a problem. And there is political corruption.

Investors who primarily allocate their capital to U.S. stocks usually don't consider these variables. But for Nu, unfavorable trends in any of these areas could derail its impressive growth story.

That said, the valuation is inviting. The stock trades at a forward price-to-earnings ratio of 14.8. At this entry point, investors might be willing to accept the risks.

Premium Feature

Moneyball Superscore

87/100

Today's Change

(

4.98

%) $

0.63

Current Price

$

13.29

The million-dollar question I believe long-term investors, particularly those looking for the potential to achieve above-normal capital appreciation, should consider Nu Holdings. As mentioned, customer, revenue, and profit growth have all been exceptional. There appears to be a sizable expansionary runway ahead as well. And as it scales up, Nu is likely developing a set of competitive strengths.

But I don't think this business has what it takes to be a millionaire maker. If you put $10,000 into the stock today, you'd need to post a monster 100-fold gain to reach the seven-figure mark. Over a 25-year time horizon, this translates to a 20% annualized rate of return. It's almost impossible to find any opportunities in the market with this kind of potential.

Nike (NKE.N) deepened its turnaround under CEO Elliott Hill, announcing a plan to shake up its operating ​model and cut more jobs after the struggling sportswear giant ‌missed analysts' expectations for quarterly revenue on Thursday.

Like many US retailers, Nike is grappling with cautious consumer spending in the face of stubborn inflation. But ​its woes have largely stemmed from strategic missteps and ​a failure to release enough new, compelling products, analysts have ⁠said, leading to an uptick in promotions and discounts. Its ​shares fell 4% in extended trading.

The company announced a new program ​to change its operating model, which includes efforts to modernize its supply chain and further reduce roles to save costs.

The program, building on its previously announced ​restructuring push, which also included job cuts, is expected to deliver ​about $2.5 billion in savings through fiscal 2031.

Nike expects its revenue to decline in ‌high-single ⁠digits in fiscal 2027. The company earlier forecast revenue to decline by a low-to-mid-single-digit percentage in the first half of fiscal 2027.

Greater China remains a weak spot for Nike, while the company also faces ​challenges in Europe

S&P ​Dow Jones Indices ⁠removed Nike from the S&P 100 (.OEX) in September as part of a quarterly rebalancing, after 18 ​years in the index of blue-chip companies.

The sportswear giant ​posted ⁠sales of $11.2 billion for the first quarter, compared with analysts' average estimate of $11.32 billion, according to data compiled by LSEG.

Its gross margin, however, ⁠rose 60 ​basis points to 42.8% in the ​quarter ended August 31, helped by lower warehousing and logistics costs.

Lyft has agreed to pay $272.5 million to settle a lawsuit accusing the ride-hailing company of violating California law by misclassifying drivers as independent contractors, instead of employees.

The company said in a regulatory filing that it believes the settlement will allow it to avoid the “costs and distraction of protracted litigation and enable management to maintain its focus on executing its business objectives.”

Lyft could not be reached for comment.

The settlement stems from a lawsuit filed by the California Labor Commissioner’s Office in August 2020 that accused Lyft of treating drivers as independent contractors rather than as employees, as required under state law at the time.

The lawsuit alleged that drivers were denied minimum wage and overtime as well as other benefits and protections provided to employees, including paid sick leave and timely wage payments.

“This settlement is about the workers who came forward and spoke up. Their voices made this outcome possible,” California Labor Commissioner Lilia García-Brower said in a statement, adding that the LCO will forgo its share of the settlement and direct those funds to drivers who filed wage claims.

The settlement, which still must be approved by a judge, covers alleged violations from April 6, 2016 to December 15, 2020 — a period California was grappling with whether workers in the booming gig economy were independent contractors or an employees.

Today, drivers for app-based transportation services like Lyft and Uber are classified as contractors after voters passed ballot measure Proposition 22 in 2020. The ballot measure provided a carve-out from Assembly Bill 5, a state law passed in 2019 that required companies like DoorDash, Lyft, and Uber to classify gig workers as employees, entitling them to minimum wage, workers’ compensation, and other benefits. 

Even after AB 5 took effect, Lyft, Uber, and other companies that relied on gig workers continued to classify their drivers as contractors. That eventually led to legal action from the LCO, California Attorney General and the City Attorneys of Los Angeles, San Diego and San Francisco, as well as private actions filed under California’s Private Attorneys General Act. The cases were coordinated in San Francisco Superior Court in September 2021.

The settlement closes this legal chapter, at least for Lyft. Uber still faces an LCO lawsuit that makes similar allegations.

When you purchase through links in our articles, we may earn a small commission. This doesn’t affect our editorial independence.

Kirsten Korosec is a reporter and editor who has covered the future of transportation from EVs and autonomous vehicles to urban air mobility and in-car tech for more than a decade. She is currently the transportation editor at TechCrunch and co-host of TechCrunch’s Equity podcast. She is also co-founder and co-host of the podcast, “The Autonocast.” She previously wrote for Fortune, The Verge, Bloomberg, MIT Technology Review and CBS Interactive.

You can contact or verify outreach from Kirsten by emailing [email protected] or via encrypted message at kkorosec.07 on Signal.

Coding approvals reflect growing clinical evidence and physician adoption of Medtronic solutions addressing urge urinary incontinence and hypertension 

, /PRNewswire/ -- Medtronic plc (NYSE: MDT), a global leader in healthcare technology, today announced that the American Medical Association (AMA) approved new Category I Current Procedural Terminology (CPT®) codes for two of its technologies, which represent important long-term growth opportunities for Medtronic: Altaviva™ implantable tibial neuromodulation device for the treatment of urge urinary incontinence and Symplicity Spyral™ renal denervation (RDN) system for the treatment of uncontrolled hypertension. The new codes, which will replace existing Category III codes, are effective January 2028.

Category I CPT® codes are permanent codes assigned to procedures the AMA has determined are well established, widely performed by physicians across the United States (U.S.), and supported by robust clinical evidence, in addition to other criteria identified in the application process. While a Category I CPT® code establishes a permanent code and can help support physician payment and inform commercial payer coverage decisions, it does not determine coverage, reimbursement, clinical superiority, or patient access.

"These Category I approvals reflect the robust clinical evidence and physician adoption for innovative solutions addressing critical gaps in care and unmet patient needs," said Lindsay Bockstedt, vice president of health economics, policy, and reimbursement at Medtronic. "The decision by AMA represents meaningful progress in the reimbursement pathway for these technologies, as Medtronic remains committed to reducing barriers to broader adoption and patient access. We're grateful to the stakeholders and clinical community whose work made this possible."

The AMA approved new Category I CPT® codes applicable to procedures associated with the following Medtronic technologies:

Altaviva™ Implantable Tibial Neuromodulation Device
The Altaviva™ device was approved by the U.S. Food and Drug Administration (FDA) in September 2025, for the treatment of urge urinary incontinence (UUI) – a condition that impacts 16 million adults in the U.S. 1 The Altaviva™ device is indicated for treatment of UUI in patients who failed or could not tolerate more conservative treatments. The device is approximately half the length of a stick of chewing gum and is placed under the skin near the ankle in a minimally invasive procedure.2 The device delivers stimulation to the tibial nerve to help restore communication between the bladder and brain to improve bladder leakage symptoms. 3-4 Unlike some other treatment options, the Altaviva™ device does not require imaging for implantation and only needs local anesthesia, and it can be activated the same day as the procedure. The system is designed to provide patients with a simple, long-lasting treatment experience, including an expected 15 years of therapy under expected therapy settings. The Altaviva™ device is also MRI-compatible from the start5, offering patients peace of mind for future medical imaging needs.

Symplicity Spyral™ Renal Denervation System
The Symplicity Spyral renal denervation (RDN) system, finalized for Medicare coverage in October 2025, is an innovative, minimally invasive procedure that delivers radiofrequency energy to nerves near the kidneys that can become overactive and contribute to high blood pressure. After sedation, the doctor inserts a single thin tube (known as a catheter) into the artery leading to the kidney. Once the tube is in place, the doctor administers energy to the system to calm the excessive activity of the nerves connected to the kidney. The tube is removed, leaving no implant behind. The Medtronic SPYRAL HTN global clinical program is the most comprehensive clinical program studying RDN in more than 5,000 patients in the presence and absence of medication, and with high baseline cardiovascular risk, and is backed by experience in over 40,000 patients globally.6-13 

About Medtronic
Bold thinking. Bolder actions. We are Medtronic. Medtronic plc, headquartered in Galway, Ireland, is the leading global healthcare technology company that boldly attacks the most challenging health problems facing humanity by searching out and finding solutions. Our Mission — to alleviate pain, restore health, and extend life — unites a global team of 95,000+ passionate people across more than 150 countries. Our technologies and therapies treat 70 health conditions and include cardiac devices, surgical robotics, insulin pumps, surgical tools, patient monitoring systems, and more. Powered by our diverse knowledge, insatiable curiosity, and desire to help all those who need it, we deliver innovative technologies that transform the lives of two people every second, every hour, every day. Expect more from us as we empower insight-driven care, experiences that put people first, and better outcomes for our world. In everything we do, we are engineering the extraordinary. For more information on Medtronic, visit www.Medtronic.com and follow Medtronic on LinkedIn.

Any forward-looking statements are subject to risks and uncertainties such as those described in Medtronic's periodic reports on file with the Securities and Exchange Commission. Actual results may differ materially from anticipated results.

CPT® codes, descriptions and other data only are copyright 2025 American Medical Association. All Rights Reserved. Applicable FARS/HHSARS apply.

Coyne KS, Wein A, Nicholson S, Kvasz M, Chen CI, Milsom I. Economic burden of urgency urinary incontinence in the United States: a systematic review. J Manag Care Pharm. 2014 Cameron AP, Chung DE, Dielubanza EJ et al. The AUA/SUFU guideline on the diagnosis and treatment of idiopathic overactive bladder (2024). J Urol. 2024;212:11-20.   Li X, Li X, Liao L. Mechanism of action of tibial nerve stimulation in the treatment of lower urinary tract dysfunction. Neuromod. 2023;27:256-266. Bhide AA, Tailor V, Fernando R, Vik K, Digesu GA. Posterior tibial nerve stimulation for overactive bladder - techniques and efficacy. Int Urogynecol J. 2020;31:865–70. M028929C001 RevC - Clinician Therapy and Programming Guide Altaviva™ Model P7850N Medtronic data on file, RDN Catheter Historical Data, Feb 2025. Data includes both Symplicity Flex and Symplicity Spyral. Kandzari DE, Townsend RR, Kario K, et al. Safety and Efficacy of Renal Denervation in Patients Taking Antihypertensive Medications. J Am Coll Cardiol. 2023 Nov 7;82(19):1809-1823. Böhm M, Kario K, Kandzari DE, et al. Efficacy of catheter-based renal denervation in the absence of antihypertensive medications (SPYRAL HTN-OFF MED Pivotal): a multicentre, randomised, sham-controlled trial. Lancet. 2020 May 2;395(10234):1444-1451.  Kario K, Ogawa H, Okumura K, et al. SYMPLICITY HTN-Japan - first randomized controlled trial of catheter-based renal denervation in asian patients -. Circ J. 2015;79(6):1222–1229. Bhatt DL, Kandzari DE, O'Neill WW, et al. A controlled trial renal denervation for resistant hypertension. N Engl J Med. April 10, 2014;370(15):1393–1401. Townsend RR, Mahfoud F, Kandzari DE, et al. Catheter-based renal denervation in patients with uncontrolled hypertension in the absence of antihypertensive medications (SPYRAL HTN-OFFMED): a randomised, sham-controlled, proof-of-concept trial. Lancet. November 11, 2017;390(10108):2160–2170. Krum H, Schlaich MP, Sobotka PA, et al. Percutaneous renal denervation in patients with treatment-resistant hypertension: final 3-year report of the Symplicity HTN-1 study. Lancet. 2014;383(9917):622–629. Medtronic data on file, RDN Catheter Historical Data, September 2026. Data includes both Symplicity Flex and Symplicity Spyral. Contacts:

Justin Paquette

Ingrid Goldberg

Public Relations

Investor Relations

+1- 612-271-7935

+1-763-505-2696

SOURCE Medtronic plc

Morgan Stanley (NYSE:MS) will release its third-quarter earnings report before the opening bell on Wednesday, Oct. 14.

Analysts expect the New York-based company to report quarterly earnings of $3.10 per share, up from $2.80 per share in the year-ago period. The consensus estimate for Morgan Stanley’s quarterly revenue is $20.52 billion. It reported $18.22 billion last year, according to Benzinga Pro.

FB Financial recently announced the completion of a $125 million subordinated notes offering due 2036.

Morgan Stanley shares fell 0.4% to trade at $187.29 on Thursday.

Benzinga readers can access the latest analyst ratings on the Analyst Stock Ratings page. Readers can sort by stock ticker, company name, analyst firm, rating change or other variables.

Let’s have a look at how Benzinga’s most-accurate analysts have rated the company in the recent period.

Evercore ISI Group analyst Glenn Schorr maintained the stock with an Outperform rating and cut the price target from $240 to $215 on Oct. 1, 2026. This analyst has an accuracy rate of 68%. Citigroup analyst Benjamin Gerlinger maintained the stock with a Neutral rating and cut the price target from $235 to $210 on Sept. 30, 2026. This analyst has an accuracy rate of 51%. HSBC analyst Domenico Santoro maintained the stock with a Hold rating and increased the price target from $215 to $219 on Sept. 28, 2026. This analyst has an accuracy rate of 55%. Wells Fargo analyst Mike Mayo maintained an Equal-Weight rating and cut the price target from $240 to $223 on Sept. 25, 2026. This analyst has an accuracy rate of 74%. UBS analyst Erika Najarian maintained the stock with a Buy rating and boosted the price target from $255 to $260 on Aug. 3, 2026. This analyst has an accuracy rate of 63%. Considering buying MS stock? Here’s what analysts think:

Photo via Shutterstock

Market News and Data brought to you by Benzinga APIs

© 2026 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

To add Benzinga News as your preferred source on Google, click here.

Nio's (NIO -0.88%) battery swap network has always been intriguing and a bit controversial to investors. If people see value in the speed of swapping batteries and using battery-as-a-service, a built-out network would be a huge competitive advantage and would unlock a higher-margin business. However, if they find it just as fast and simple to charge vehicles at a fast-charging network, Nio's battery swapping stations could turn into a big waste of time, effort, and, of course, capital.

All that said, the game just completely changed with the announcement that Geely is "buying" into Nio's battery swap network. Here are the details, and what investors have to know.

The fine print Nio recently announced that a Geely Holding subsidiary, assuming regulatory approval, will soon hold a 30% stake in NIO Power, Nio's subsidiary that runs its battery swapping network. While the deal values NIO Power at roughly $2.4 billion, Geely is mostly avoiding cash outflows. Instead, it's contributing its own commercial battery swap business (Yiyi Internet Technology) and about $94 million for the 30% stake in NIO Power. In a second transaction, Nio is purchasing a 10% stake in Haohan Energy, which is Geely's charging business.

This development does a couple of positive things for Nio and its investors.

Image source: Nio.

First, adding a massive automaker such as Geely to Nio's battery swap network accelerates its path to profitability. Simply put, Nio doesn't have the volume of vehicles on the road needing battery swaps to use swap stations to a breakeven level. It's been estimated that each station needs to average about 60 battery swaps a day to break even. While utilization rates appear to be improving, Nio doesn't consistently disclose the information.

Second, Nio purchasing a 10% stake in Geely's Haohan Energy immediately opens access to Geely's ultra-fast megawatt charging technology, without Nio needing to fork out massive research and development spending to build its own version. Nio and Geely intend to fully connect their charging infrastructure.

Lastly -- and this might be the big takeaway -- this makes vehicles cheaper for Geely customers to purchase upfront, because it can now use Nio's battery-as-a-service model that takes the battery off the invoice. It's also a huge step for Nio to become the "gold standard" for China's battery standards.

Nio is trying to make its battery swap network profitable with a user base pooled from its 1.26 million cumulative vehicle sales. Bringing in a partner such as Geely that can eventually work Nio's battery swap specifications into its vehicles would drastically increase its potential user base and strengthen Nio's ability to lower battery swap station overhead and improve margins.

In fact, if Nio continues getting automakers to buy into its battery standards, allowing non-Nio vehicles to use the charging stations, it could open the door to the more than 370 million vehicles in use in China, per China's Ministry of Public Security and Ministry of Commerce.

Premium Feature

Moneyball Superscore

66/100

Today's Change

(

-0.88

%) $

-0.03

Current Price

$

3.40

The three-way war Whether Nio's battery swap network turns into a massive competitive advantage -- perhaps even evolving into a higher-margin business that becomes more lucrative than its traditional vehicle sales business over the next two decades -- or whether the network turns into a poorly utilized black hole of profits comes down to which technology and strategy wins. The positions are becoming entrenched among Nio and Geely's unified battery-swapping ecosystem, CATL's independent "Choco-Swap" network, and BYD Co.'s gamble on its ultra-fast megawatt flash-charging stations.

For investors, while this transaction won't load Nio's coffers with cash, or directly split costs of developing its battery swapping network, bringing Geely vehicle owners into the ecosystem unlocks massive potential. It's also much closer to becoming the standard for battery swaps in China. That could one day be a brilliant and lucrative victory.

Investment firms Petersen Energia and Eton Park petitioned the U.S. Supreme Court on Wednesday ​to reinstate a $16.1 billion judgment against Argentina in the long-running ‌YPF litigation.

The petition seeks to overturn a March decision by the 2nd U.S. Circuit Court of Appeals, which held the claims belonged in Argentine courts rather than the United ​States. That decision overturned a judgment entered after more than a ​decade of litigation. The investors argue the ruling improperly allows a ⁠foreign nation to rely on its own laws to avoid liability ​in U.S. courts.

BACKGROUND

The dispute centers on Argentina's 2012 nationalization of a controlling stake in ​YPF. Petersen and Eton Park allege Argentina violated YPF's bylaws by failing to launch a tender offer to minority shareholders after seizing a 51% stake from Spain's Repsol.

Argentina amended ​YPF's bylaws prior to its 1993 New York Stock Exchange listing to ​require a mandatory tender offer to all shareholders if the government ever regained majority ‌control.

A ⁠U.S. district court had previously entered a $16.1 billion judgment — described in the petition as the largest commercial award in U.S. history — after a three-day damages trial.

KEY ARGUMENTS

The petition asks whether a foreign sovereign can use its own law ​to require claims ​to be brought ⁠to its domestic courts despite jurisdiction established under the Foreign Sovereign Immunities Act.

It also questions whether U.S. courts should ​defer to a sovereign's interpretation of its own law ​when that ⁠interpretation is first advanced on appeal.

The petition, filed by former U.S. Solicitor General Paul Clement, argues the 2nd Circuit decision conflicts with Supreme Court precedent and ⁠creates ​a split among federal appellate courts.

Argentina's presidential ​office did not immediately respond to requests for comment. YPF declined to comment.

Sixty-five consecutive quarters of quarterly common stock dividend increases  | Source: Bank OZK

LITTLE ROCK, Ark., Oct. 01, 2026 (GLOBE NEWSWIRE) -- Bank OZK (the “Bank”) (Nasdaq: OZK) announced its Board of Directors declared a quarterly cash dividend on the Bank’s common stock of $0.49 per share, up $0.01, or 2.08% from the prior quarter. The common stock dividend is payable on October 20, 2026 to shareholders of record as of October 13, 2026. This marks the Bank’s 65th consecutive increase in its quarterly common stock dividend.

The Board of Directors also declared a quarterly cash dividend of $0.28906 per share on the Bank’s 4.625% Series A Non-Cumulative Perpetual Preferred Stock (“Series A Preferred Stock”) (Nasdaq: OZKAP) for the period covering August 15, 2026 through, but excluding November 15, 2026. The Series A Preferred Stock dividend is payable on November 16, 2026, to holders of record of the Series A Preferred Stock at the close of business on November 2, 2026.

Bank OZK’s consistent track record of increasing its common stock dividend has led to it being included in the S&P High Yield Dividend Aristocrats® index (Ticker: SPHYDA) since January 2018. The index consists of members of the S&P Composite 1500® that have followed a managed-dividends policy of consistently increasing common stock dividends every year for at least 20 years, and that meet minimum float-adjusted market capitalization and liquidity requirements. For more information on the index, visit www.spglobal.com/spdji.

GENERAL INFORMATION
Bank OZK (Nasdaq: OZK) is a regional bank providing innovative financial solutions delivered by expert bankers with a relentless pursuit of excellence. Established in 1903, Bank OZK conducts banking operations in 267 offices in nine states including Arkansas, Georgia, Florida, Texas, North Carolina, Tennessee, New York, California and Mississippi and had $41.7 billion in total assets as of June 30, 2026. For more information, visit ozk.com.

Investor Relations Contact:Jay Staley (501) 906-7842Media Contact:Michelle Rossow (501) 906-3922  

St. Louis, Oct. 01, 2026 (GLOBE NEWSWIRE) -- ESCO Technologies Inc. (NYSE: ESE) today announced that it has completed the acquisition of the Megger Group Limited (Megger) business of TBG AG (TBG). Under the terms of the transaction, TBG has agreed to certain lock-up provisions with respect to its equity ownership in ESCO common stock and has nomination rights for one seat on ESCO’s Board of Directors. 

The acquisition of Megger supports ESCO’s long-term objective of expanding our leadership positions in high-growth end-markets. Megger is a leading global provider of testing, monitoring, and data-driven solutions for utilities and critical electric infrastructure and will become a part of our Utility Solutions Group segment. Megger adds a well-respected and differentiated product portfolio, with highly complementary capabilities, deep technical expertise, and strong customer and supplier relationships.   The addition of Megger expands the scale and international reach of ESCO’s utility product offerings, further strengthening our position as a valued partner to utilities worldwide.

The Company’s FY 2027 financial guidance and outlook, inclusive of impacts from the Megger acquisition, will be announced in November when Q4 2026 earnings are released.

ESCO is a global provider of highly engineered products and solutions serving diverse end-markets. It manufactures filtration and fluid control products, advanced composites, as well as signature and power management solutions for aviation, Navy, space, and industrial customers. ESCO is an industry leader in designing and manufacturing RF test and measurement products and systems; and provides diagnostic instruments, software and services to industrial power users and the electric utility and renewable energy industries. Headquartered in St. Louis, Missouri, ESCO and its subsidiaries have offices and manufacturing facilities worldwide. For more information on ESCO and its subsidiaries, visit ESCO’s website at www.escotechnologies.com.

SOURCE ESCO Technologies Inc.
Kate Lowrey, Vice President of Investor Relations, (314) 213-7277